Current Cardiology Reports最新文献_第10页

Improving the Prioritization of Heart Transplantation Candidates for Optimal Clinical Outcomes: A Narrative Review. 改善心脏移植候选人的优先级以获得最佳临床结果：一篇叙述性综述。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-08 DOI: 10.1007/s11886-024-02150-2

Phan Quang Thuan, Cao Dang Khang, Nguyen Hoang Dinh

{"title":"Improving the Prioritization of Heart Transplantation Candidates for Optimal Clinical Outcomes: A Narrative Review.","authors":"Phan Quang Thuan, Cao Dang Khang, Nguyen Hoang Dinh","doi":"10.1007/s11886-024-02150-2","DOIUrl":"10.1007/s11886-024-02150-2","url":null,"abstract":"Purpose of review: This narrative review evaluates the limitations of current heart transplantation allocation models, which prioritize medical urgency and waitlist time but fail to adequately predict long-term post-transplant outcomes. It aims to identify advanced metrics that can strengthen the prioritization framework while addressing persistent racial, geographic, and socioeconomic inequities in access to transplantation.Recent findings: Recent research indicates that incorporating frailty, nutritional status, immunological compatibility, and pulmonary hemodynamics into allocation frameworks can enhance the prediction of transplant outcomes. The growing use of mechanical circulatory support (MCS) as a bridge to transplantation provides stabilization for critically ill patients; however, disparities in access persist. Studies continue to emphasize the barriers faced by minority and pediatric populations, highlighting the need for expanded donor networks and improved matching criteria. This review highlights the necessity of shifting transplantation prioritization toward multidimensional candidate evaluations that consider both clinical complexity and long-term outcomes. Policy reforms aimed at addressing healthcare disparities and optimizing donor utilization are crucial for improving patient outcomes. Future research should focus on assessing the effectiveness of advanced allocation models, such as continuous distribution frameworks, to promote equitable and sustainable transplantation systems.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"8"},"PeriodicalIF":3.1,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcatheter Caval Implantation for Severe Tricuspid Regurgitation. 经导管腔内植入治疗严重三尖瓣反流。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-07 DOI: 10.1007/s11886-024-02190-8

Vincent Chen, Omar Abdul-Jawad Altisent, Rishi Puri

{"title":"Transcatheter Caval Implantation for Severe Tricuspid Regurgitation.","authors":"Vincent Chen, Omar Abdul-Jawad Altisent, Rishi Puri","doi":"10.1007/s11886-024-02190-8","DOIUrl":"10.1007/s11886-024-02190-8","url":null,"abstract":"Purpose of review: We describe the evolution of caval valve implantation (CAVI) as a treatment for severe symptomatic tricuspid regurgitation (TR) in the high surgical risk patient.Recent findings: Surgical treatment of severe TR is often limited by the high surgical risk of the patients who tend to develop severe secondary TR. Coaptation, annuloplasty, and orthotopic replacement strategies are all limited by annular and leaflet geometry, prior valve repair, and the presence of cardiac implantable device leads. CAVI appears to be a treatment strategy for severe symptomatic TR that improves functional capacity and quality of life while also reducing edema and ascites and improving cardiac output. Chronic kidney disease is a common comorbidity of patients with severe TR; zero-contrast CAVI has been described. Severe TR is undertreated, yet common in the elderly structural heart disease population. The evolution of CAVI as a viable treatment for severe TR underscores the deleterious systemic contribution of backwards flow to morbidity and mortality. There are good safety and efficacy outcomes from registry data using the TricValve platform. Randomized controlled trials for CAVI versus medical therapy for severe TR are ongoing.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"7"},"PeriodicalIF":3.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing Myocarditis Research: Evaluating Animal Models for Enhanced Pathophysiological Insights. 推进心肌炎研究：评估动物模型以增强病理生理学见解。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-07 DOI: 10.1007/s11886-024-02182-8

Yanzhe Xu, Yixing Tan, Zhonghui Peng, Meiyu Liu, Bi Zhang, Ke Wei

{"title":"Advancing Myocarditis Research: Evaluating Animal Models for Enhanced Pathophysiological Insights.","authors":"Yanzhe Xu, Yixing Tan, Zhonghui Peng, Meiyu Liu, Bi Zhang, Ke Wei","doi":"10.1007/s11886-024-02182-8","DOIUrl":"10.1007/s11886-024-02182-8","url":null,"abstract":"Purpose of review: This review aims to assess the current landscape of animal models used in myocarditis research, with a focus on understanding their utility in uncovering the pathophysiology of the disease. The goal is to evaluate these models' strengths and weaknesses and propose optimizations to make them more relevant and reliable for both mechanistic studies and therapeutic interventions in myocarditis.Recent findings: Recent studies have primarily utilized animal models, particularly viral and autoimmune myocarditis models, to study disease mechanisms. Coxsackievirus remains the most common virus used in viral myocarditis models, offering high success rates but limited applicability to human cases due to differences in infection patterns. Autoimmune myocarditis models, often involving humanized mice, have made strides in mimicking human immune responses but still face challenges in accuracy and clinical relevance. COVID-19 has introduced new avenues for research, especially concerning vaccine-induced myocarditis, although findings remain preliminary. Animal models remain crucial for myocarditis research, but each comes with distinct challenges. Viral models excel in success rate but suffer from partial relevance to human conditions. Autoimmune models are useful in immunological studies, though costly and less replicable. Vaccine-associated models are closely related to modern clinical conditions, but lack theoretical support and therefore lack reliability. Optimizing these models could improve our understanding of myocarditis and lead to more effective treatments. Future research should aim to refine these models to better simulate human conditions and enhance their clinical applicability, ultimately advancing the diagnosis and treatment of myocarditis.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"6"},"PeriodicalIF":3.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sepsis-Associated Cardiomyopathy: Long-Term Prognosis, Management, and Guideline-Directed Medical Therapy. 败血症相关心肌病：长期预后、管理和指导药物治疗

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-07 DOI: 10.1007/s11886-024-02175-7

Steven M Hollenberg

{"title":"Sepsis-Associated Cardiomyopathy: Long-Term Prognosis, Management, and Guideline-Directed Medical Therapy.","authors":"Steven M Hollenberg","doi":"10.1007/s11886-024-02175-7","DOIUrl":"10.1007/s11886-024-02175-7","url":null,"abstract":"Purpose of review: To explore the definitions of sepsis-induced cardiomyopathy and how that impacts interpretation of the available data and considerations of long-term prognosis and management.Recent findings: The field of sepsis-induced cardiomyopathy has been hampered by lack of consensus about its proper definition, with a great deal of heterogeneity in clinical trial data in both individual studies and meta-analyses and consequent disparity of estimates of incidence, prognosis, and clinical significance. New diagnostic techniques, while potentially shedding light on pathophysiology, have only exacerbated these challenges. There are few persuasive data to suggest that decreased ejection fraction consequent to sepsis-induced cardiomyopathy merits a treatment strategy different from other causes, except that improvement may be more likely inasmuch as the classic description includes reversibility over 7 to 10 days. For persistent cardiac dysfunction after sepsis, whether pre-existing or newly diagnosed, institution and titration of guideline-directed medical therapy for HFrEF seems to be the most logical strategy. Armed with a clear understanding of what parameters of cardiac function are most important, clinicians can develop therapeutic strategies that make sense and calibrate them according to the clinical response.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"5"},"PeriodicalIF":3.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk and Protective Factors of Poor Clinical Outcomes in Heart Failure with Improved Ejection Fraction Population: A Systematic Review and Meta-Analysis. 射血分数改善的心力衰竭患者临床预后不良的风险和保护因素：一项系统回顾和荟萃分析。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-06 DOI: 10.1007/s11886-024-02180-w

Wilbert Huang, Apridya Nurhafizah, Alvin Frederich, Alya Roosrahima Khairunnisa, Capella Kezia, Muhammad Irfan Fathoni, Sean Samban, Samuel Flindy

{"title":"Risk and Protective Factors of Poor Clinical Outcomes in Heart Failure with Improved Ejection Fraction Population: A Systematic Review and Meta-Analysis.","authors":"Wilbert Huang, Apridya Nurhafizah, Alvin Frederich, Alya Roosrahima Khairunnisa, Capella Kezia, Muhammad Irfan Fathoni, Sean Samban, Samuel Flindy","doi":"10.1007/s11886-024-02180-w","DOIUrl":"https://doi.org/10.1007/s11886-024-02180-w","url":null,"abstract":"Aims: Heart failure with improved ejection fraction (HFimpEF) patients could still develop adverse outcomes despite EF improvement. This study evaluates the risk and protective factors of poor clinical outcomes in HFimpEF patients.Methods: Systematic searching was done to include studies that evaluate the risks of developing poor outcomes in HFimpEF patients. HFimpEF is defined as improvement of 5-10% EF within 6-12 months or normalization of EF > 40%. Poor clinical outcome is defined as a composite of all-cause mortality, cardiovascular events, HF rehospitalization, and requirement of LVAD/ transplant. Odds ratios of outcome are pooled with random effects model. A subgroup analysis of multivariate analysis-only studies was also conducted.Results: 32 studies comprising 10,740 HFimpEF patients are included. Poor clinical outcomes followed up for approximately 3 years, are seen in 18.9% of HFimpEF patients. Twelve statistically significant factors that increase the risk of outcome are found. Among them, anemia (OR 7.69, CI 3.48-16.99, I2 0%) and baseline NT pro-BNP (OR 3.25) are the two most important predictors. Other significant risk factors are increasing age, ischemic heart disease, NYHA III/IV, diabetes mellitus, atrial fibrillation, dyslipidemia, cerebrovascular disease, hypertension, use of diuretics, and baseline LVEDD. Alternately, protective factors of poor clinical outcome are regression of left atrial diameter (LAD) (OR 0.33, CI: 0.18-0.61, p 0.0003, I2 0%), use beta-blockers, SGLT- 2 inhibitors, and baseline LVEF level (OR 0.60, 0.78, 0.90, respectively).Conclusion: HFimpEF patients are not fully recovered and patient stratification based on risk and protective factors is recommended.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"4"},"PeriodicalIF":3.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Emerging Role of Multimodality Imaging in the Diagnosis and Management of Post Pericardiotomy Syndrome. 多模态影像学在心包切开术后综合征诊断和治疗中的新作用。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-04 DOI: 10.1007/s11886-024-02158-8

Mohammad Alqahtani, Vartan Mardigyan, Michael Chetrit

{"title":"The Emerging Role of Multimodality Imaging in the Diagnosis and Management of Post Pericardiotomy Syndrome.","authors":"Mohammad Alqahtani, Vartan Mardigyan, Michael Chetrit","doi":"10.1007/s11886-024-02158-8","DOIUrl":"https://doi.org/10.1007/s11886-024-02158-8","url":null,"abstract":"Purpose of review: This review aims to evaluate current diagnostic and therapeutic strategies for postpericardiotomy syndrome (PPS), with a focus on the evolving role of multimodality imaging, including echocardiography, cardiac computed tomography (CCT), and cardiac magnetic resonance imaging (CMR). The review also explores the potential benefits of advanced imaging in improving the accuracy and management of PPS.Recent findings: PPS, a common complication following cardiac surgery, presents with pleuritic chest pain, fever, and pericardial or pleural effusion. Traditional diagnostic methods like echocardiography and X-ray are increasingly supplemented by advanced imaging modalities such as CCT and CMR. These tools allow for better visualization of pericardial inflammation and effusion, aiding in diagnosis and guiding treatment. Colchicine and NSAIDs remain the most effective treatments for PPS, while the role of corticosteroids remains uncertain. Biological treatments have shown promising results in managing recurrent pericarditis. This review presents a proposed algorithm for the diagnosis and management of PPS, drawing on our institutional experience. Multimodality imaging is emerging as an essential tool in diagnosing and managing PPS. It enhances diagnostic precision, informs treatment strategies, and provides prognostic insights. As imaging technology advances, integrating these modalities into PPS care has the potential to improve patient outcomes.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"1"},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary Intervention Outcomes in Patients with Liver Cirrhosis. 肝硬化患者冠状动脉介入治疗的结果。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-04 DOI: 10.1007/s11886-024-02163-x

Song Peng Ang, Jia Ee Chia, Jose Iglesias, Muhammed Haris Usman, Chayakrit Krittanawong

{"title":"Coronary Intervention Outcomes in Patients with Liver Cirrhosis.","authors":"Song Peng Ang, Jia Ee Chia, Jose Iglesias, Muhammed Haris Usman, Chayakrit Krittanawong","doi":"10.1007/s11886-024-02163-x","DOIUrl":"10.1007/s11886-024-02163-x","url":null,"abstract":"Purpose of review: This review assesses the outcomes of coronary interventions in patients with liver cirrhosis and coronary artery disease (CAD), focusing on the clinical challenges posed by cirrhosis-related hemodynamic and coagulopathic changes. It highlights essential considerations for managing these patients, who have an increased risk of adverse events during coronary procedures.Recent findings: Recent studies have shown that patients with liver cirrhosis undergoing PCI experience significantly higher mortality rates compared to non-cirrhotic patients, particularly in the context of STEMI and NSTEMI. Coagulopathy and thrombocytopenia increase the risk of bleeding and vascular complications during interventions. Radial access has been suggested as a safer alternative to femoral access in these patients due to reduced bleeding complications. Additionally, contrast-induced nephropathy (CIN) is a prevalent risk, with cirrhotic patients demonstrating higher rates of acute kidney injury post-PCI. Preventive strategies such as minimizing contrast exposure and utilizing intravascular ultrasound (IVUS) are recommended. Managing CAD in cirrhotic patients requires careful consideration of their unique pathophysiological state. Higher in-hospital mortality, bleeding risks, and vascular complications necessitate tailored procedural strategies, such as radial access and contrast minimization. The balance between thrombotic and bleeding risks is critical in decision-making, with IVUS and hydration strategies being promising approaches. Further research is required to optimize treatment protocols and improve long-term outcomes for this high-risk population.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"2"},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142925980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications. 心肌疾病在系统性硬化症：最近的更新和临床意义。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2025-01-04 DOI: 10.1007/s11886-024-02164-w

Ryan Osgueritchian, Hoda Mombeini, Vivek P Jani, Steven Hsu, Laura K Hummers, Fredrick M Wigley, Stephen C Mathai, Ami A Shah, Monica Mukherjee

{"title":"Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications.","authors":"Ryan Osgueritchian, Hoda Mombeini, Vivek P Jani, Steven Hsu, Laura K Hummers, Fredrick M Wigley, Stephen C Mathai, Ami A Shah, Monica Mukherjee","doi":"10.1007/s11886-024-02164-w","DOIUrl":"10.1007/s11886-024-02164-w","url":null,"abstract":"Purpose of review: The present review aims to address systemic sclerosis (SSc)-associated myocardial disease, a significant cause of morbidity and mortality, by examining the mechanisms of inflammation, microvascular dysfunction, and fibrosis that drive cardiac involvement. The objective is to elucidate critical risk factors and explore advanced diagnostic tools for early detection, enhancing patient outcomes by identifying those at highest risk.Recent findings: Recent studies underscore the importance of specific autoantibody profiles, disease duration, and cardiovascular comorbidities as key risk factors for severe cardiac manifestations in SSc. Additionally, advanced imaging techniques and biomarker analyses have emerged as pivotal tools for early identification and risk stratification. These innovations enable clinicians to detect subclinical myocardial involvement, potentially averting progression to symptomatic disease. SSc-associated myocardial disease remains challenging to predict, yet novel imaging modalities and biomarker-guided strategies offer a promising pathway for early diagnosis and targeted intervention. Integrating these approaches may enable more effective early detection and screening strategies as well as mitigation of disease progression, ultimately enhancing clinical outcomes for patients with SSc at-risk for adverse clinical outcomes.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"3"},"PeriodicalIF":3.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis. 降尿酸药物的心血管疗效：一项 Meta 分析

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-12-01 Epub Date: 2024-10-01 DOI: 10.1007/s11886-024-02138-y

Yasser Jamil, Dana Alameddine, Mahmoud El Iskandarani, Ankit Agrawal, Aro D Arockiam, Elio Haroun, Heba Wassif, Patrick Collier, Tom Kai Ming Wang

{"title":"Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis.","authors":"Yasser Jamil, Dana Alameddine, Mahmoud El Iskandarani, Ankit Agrawal, Aro D Arockiam, Elio Haroun, Heba Wassif, Patrick Collier, Tom Kai Ming Wang","doi":"10.1007/s11886-024-02138-y","DOIUrl":"10.1007/s11886-024-02138-y","url":null,"abstract":"Background: Although hyperuricemia is a recognized risk factor for cardiovascular diseases, mixed results have been reported regarding the associations between uric acid-lowering medications and cardiovascular events. This meta-analysis compared the cardiovascular outcomes of different uric acid-lowering medications and placebo.Methods: Following PRISMA guidelines, we searched OVID Medline, Embase, Web of Science, and Cochrane databases to identify potentially relevant articles until December 2023. Studies must be randomized or observational, report cardiovascular and mortality outcomes, and compare uric acid-lowering medications to placebo or each other. Data was analyzed using Revman (version 5.4) software.Results: A total of 3,393 studies were searched, after which 47 studies were included, totaling 3,803,509 patients (28 studies comparing xanthine oxidase inhibitors (XOI) versus placebo, 17 studies comparing allopurinol and febuxostat, and 2 studies comparing XOI and uricosuric agents). Overall mean age was 57.3 years, and females comprised 20.8% of all studies. There were no significant differences between XOI and placebo for cardiovascular outcomes (mortality, myocardial infarction, major adverse cardiovascular events, heart failure, or arrhythmia). There was significant heterogeneity in all these pooled analyses. Comparing Allopurinol to Febuxostat, there was a lower risk of heart failure in febuxostat than allopurinol in 3 RCTs (OR 0.66, 95% CI 0.50-0.89, p = 0.006). Other cardiovascular outcomes were not different. Lastly, when comparing XOI and uricosuric agents, no significant differences in MI rates were evident.Conclusion: XOI was not associated with reduced cardiovascular events compared to placebo. When comparing XOI agents, Febuxostat might reduce the risk of HF, but future studies are required to confirm the findings from the current study.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1427-1437"},"PeriodicalIF":3.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosing Non-Ischemic Cardiomyopathies on Myocardial Perfusion Imaging with Positron Emission Tomography. 利用正电子发射断层扫描心肌灌注成像诊断非缺血性心肌病。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-12-01 Epub Date: 2024-09-21 DOI: 10.1007/s11886-024-02139-x

Roopesh Sai Jakulla, Brett W Sperry

{"title":"Diagnosing Non-Ischemic Cardiomyopathies on Myocardial Perfusion Imaging with Positron Emission Tomography.","authors":"Roopesh Sai Jakulla, Brett W Sperry","doi":"10.1007/s11886-024-02139-x","DOIUrl":"10.1007/s11886-024-02139-x","url":null,"abstract":"Purpose of review: This article summarizes findings seen in various cardiomyopathies on myocardial perfusion imaging (MPI) with positron emission tomography (PET).Recent findings: MPI is the cornerstone for evaluation of coronary ischemia, and technological advancements have yielded improved imaging quality and reduction in radiation exposure, particularly with PET. Multi-specialty guidelines and appropriate use criteria provide guidance on utilization of PET MPI in various scenarios related to evaluation of chest pain, new onset cardiomyopathy, and other scenarios where coronary ischemia should be assessed. Various non-ischemic cardiomyopathies such as septal and apical hypertrophic cardiomyopathy, amyloidosis, sarcoidosis, takotsubo, and dilated cardiomyopathy have typical imaging findings on PET MPI and can be identified if these patterns are understood. It is essential to recognize specific imaging patterns in non-ischemic cardiomyopathies which may aide in diagnosis. Ultimately, multimodality imaging, including echocardiography and cardiac magnetic resonance, complement PET MPI in diagnosing and guiding treatment options for these conditions.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1439-1445"},"PeriodicalIF":3.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0